Tirzepatide's gastrointestinal adverse effects could lead to dehydration and in turn a deterioration in renal function including acute renal failure. Older people and some other groups of people may ...

Tirzepatide should be thought about as an option for individual people in line with NICE's guideline on overweight and obesity management. The visual summary care pathway has an overview. Table 4 is ...

The 4 technology appraisal committees are standing advisory committees of NICE. This topic was considered by committee A. Committee members are asked to declare any interests in the technology being ...

Tirzepatide is recommended as an option for managing overweight and obesity, alongside a reduced-calorie diet and increased physical activity in adults, only if they have: an initial body mass index ...

Cisplatin is a powerful chemotherapy medicine which is routinely used to treat many cancers in children. Over time, cisplatin builds up in the inner ear and can cause inflammation and damage, known as ...

NICE inherited the 7 highly specialised technologies (HST) routing criteria from AGNSS (Advisory Group for National Specialised Services) in 2013. Following that, the NICE Highly Specialised ...

Our final draft guidance recommends elacestrant (also called KORSERDU and made by Menarini Stemline) for treating oestrogen receptor-positive, human epidermal growth factor receptor 2-negative (HER2-) ...

Ruxolitinib for treating acute graft versus host disease refractory to corticosteroids in people aged 12 and over [ID6377] Draft guidance Technology appraisal guidance 10 January 2025 Cladribine for ...

We have a library of over 200 quality standards and a single menu of indicators. They can be used to help define and measure quality in health, public health and social care. They can be used by ...

Suggested remit: To appraise the clinical and cost effectiveness of Donidalorsen within its marketing authorisation for treating angioedema.

Suggested remit: To appraise the clinical and cost effectiveness of Doxecitine–doxribtimine within its marketing authorisation for treating Thymidine Kinase 2 (TK2) deficiency.